The evolution of the therapeutic concept ‘GIP receptor antagonism’
Glucose-dependent insulinotropic polypeptide (GIP) is an intestinal hormone that potentiates glucose-induced insulin secretion in the postprandial state. GIP exerts a broad range of other physiological actions e.g. in the pancreas, bone tissue, and vasculature. In more than 20 years, GIP receptor an...
Saved in:
| Main Authors: | Frederikke Koefoed-Hansen, Mads Marstrand Helsted, Hüsün Sheyma Kizilkaya, Asger Bach Lund, Mette Marie Rosenkilde, Lærke Smidt Gasbjerg |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1570603/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Physiology and clinical applications of GIP
by: Shunsuke Yamane, et al.
Published: (2025-07-01) -
The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis
by: Bashaier Al-Zaid, et al.
Published: (2025-03-01) -
The role of GIPR in food intake control
by: Paula-Peace James-Okoro, et al.
Published: (2025-03-01) -
Glucose-dependent insulinotropic polypeptide (GIP)
by: Timo D. Müller, et al.
Published: (2025-05-01) -
Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01)